Skip to main content
メニュー
Revvity logo
Contact us
JP
Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong (China) *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Breadcrumb
...
  • ホーム
  • Products
  • 研究・開発
  • 研究ソリューション
    • ゲノム解析
    • タンパク質解析
    • 細胞分析
    • 研究ソリューション
  • 医薬品開発
    • Biomarker Discovery
    • 細胞・遺伝子治療
    • GMP Workflows
    • Immunoassays Solutions
    • pHSense Reagents
    • バイオロジクス
    • 低分子創薬
    • 疾患研究
    • ターゲットクラス
    • 医薬品開発
    • プレシジョン・メディシン・リサーチ
    • 機能ゲノミクススクリーニングソリューション
    • アッセイ開発ワークフロー
    • Microphysiological Systems
    • Biobanking Workflows
    • Agrigenomics Workflows
  • ADME/Tox Studies
    • ADME/Tox Studies
    • Drug Repurposing

ADME/Tox Studies

Investigate the efficacy and safety of your drug candidate

In the development phase of a new drug product, researchers must examine the activity of a compound in relevant model systems that can mimic human physiology to assess its safety and toxicity. Drug metabolism and pharmacokinetics testing, such as absorption, distribution, metabolism, and excretion (ADME) and toxicology studies, are a critical step in this process.

ADME and toxicology studies are conducted during the preclinical stage of drug development process before filing an Investigational New Drug (IND) application, prior to any clinical trial. Many early candidates are prevented from reaching the market due to inappropriate ADME properties and drug-induced toxicity.

Tools that help to predict the ADME responses early in development present an advantage to researchers as they mitigate the risk of late-stage failure. For example, in vitro metabolite profiling, structural activity elucidation, and drug-drug interaction (DDI) studies are critical for IND and New Drug Application (NDA) submissions during preclinical development. Selecting appropriate in vitro assays and animal models is also imperative.

We provide comprehensive and innovative line of instrumentation, software, reagents, and consumables, as well as advanced informatics and services that could assist our customers to meet compliance requirements throughout the ADME/tox studies.

Key benefits:
  • Comprehensive solutions for ADME and toxicity studies.
  • Advanced tools for detailed pharmacokinetics analysis.
  • Optimized techniques for drug metabolism and excretion research.
  • Advanced evaluation methods for drug safety. 


For research use only. Not for use in diagnostic procedures.

ADME-Tox Studies

ご質問がございましたら、
お気軽にお問い合わせください。

お問合せ
Revvity Logo

©2025 Revvity - All rights reserved

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.